GlaxoSmithKline to axe 120 jobs An injection of taxpayer cash into GlaxoSmithKline is under review after the pharmaceutical company announced it will axe 120 Melbourne jobs. The redundancies will be at the company's Boronia site, which employs 363 people. In February last year, the Victorian government announced it was a key supporter of a $60 million planned expansion of the site, boasting it would create 58 new highly skilled jobs by 2017. Premier Denis Napthine on Wednesday said the government would review whether to go ahead with the significant funding package. "We have yet to pay that money to Glaxo," he said. We will now review the contract that we have with Glaxo to make sure that they deliver on their terms of that contract with regard to jobs in this state. Dr Napthine said he could not disclose how much the contract with Glaxo was worth for commercial reasons. He said the government would work with the company to ensure those workers laid-off received appropriate entitlements. Boronia site director Troy Webb said the job losses come as the company abandoned its tablet packaging business to focus on technology manufacturing. "Any redundancy will not come into effect immediately as the process will take some time to account for regulatory requirements of affected markets," he said. The research-based healthcare company provides medicines, vaccines and over-the-counter healthcare products. GlaxoSmithKline employs 1500 people around Australia.